Gliogene®
This test is crucial for the accurate classification of tumors, significantly influencing the therapy strategy for patients.
What is a glioma?
Gliomas represent a genetically, histologically, and clinically diverse category of tumors found in the central nervous system (brain or spinal cord) or the peripheral nervous system. They can originate from many neuroglial cell types, and their subcategorization is crucial for differential diagnosis, management, and therapy of patients.
What is the significance of the test?
The examination holds significance for the subsequent reasons:
Differential diagnosis: The examination aids in the accurate differential diagnosis of gliomas to identify the specific tumor type. The significance lies in the fact that various glioma forms necessitate distinct treatment strategies and exhibit differing prognoses.
Prediction: The test can assist in the prognosis of the condition to ascertain the patient’s life expectancy.
changes in the IDH1 and IDH2 genes correlate with improved illness prognosis and enhanced efficacy of radiotherapy, but changes in the BRAF gene are linked to responsiveness to BRAF inhibitor treatment. Methylation of the MGMT gene promoter provides a survival benefit, especially in elderly patients with high-grade gliomas. This can assist patients and their families in comprehending the issue more effectively and formulating suitable plans.
The selection of a suitable treatment can be facilitated by testing, as some biomarkers are associated with responses to various therapies. The concurrent co-deletion of chromosomal regions 1p and 19q is associated with a favorable clinical outcome and predicts responsiveness to alkylating systemic therapy.
Exemplary Report of findings
Specifications for Gliogene® Test
- The examination employs contemporary molecular methodologies like NGS, FISH, and Real-time PCR.
- These technologies provide the concurrent investigation of genetic biomarkers, which, when integrated with histopathological data, yield a full overview for enhanced clinical care of each patient.
Low-grade gliomas (grades I and II):
- Alterations in the IDH1 and IDH2 genes
- Methylation of the MGMT gene promoter
- High-grade gliomas (grades III and IV): Mutations in the IDH1 and IDH2 genesAlterations in the BRAF geneCo-deletion of chromosomal loci 1p and 19q.
Ten business days
For the Gliogene® analysis, we require either the paraffin block from the tumor or uncolored paraffin slices mounted on slides (air-dried, not oven-dried). Specifically, we require four portions of 3μm and six sections of 10μm.
The Customer Service Department will furnish you with a distinct e-banking payment code, or payment may be executed via card or bank transfer.
Scipharm is accountable for all requisite procedures pertaining to the receipt and return of your sample. Please contact us to coordinate sample collection and return.
Your results will be transmitted to your physician through a secure network and to you via email, accompanied by a secure unique code supplied by customer support.
The Customer Service Team is dedicated to addressing your inquiries regarding the services provided by Genekor. If you are interested in any testing provided by scipharm please contact us directly.
To finalize the test, you must complete and submit the Consent form located here.
